Page 101 - Veterinary Immunology, 10th Edition
P. 101

VetBooks.ir  Activation Pathways





               The Alternative Pathway


               The alternative pathway is an evolutionary ancient innate pathway.
               It is triggered when microbial cell walls meet complement proteins
               in the blood.

                  The most important complement protein is called C3. C3 is a
               disulfide-linked heterodimer with α and β chains. It is synthesized
               by liver cells and macrophages and is the most abundant
               complement component in serum. C3 has a reactive thioester side-
               chain, that, when activated, binds to microbes and marks them for

               destruction by immune cells. Activation of this thioester side-chain
               must be carefully regulated to ensure that C3 does not bind to
               normal cells. To prevent such accidents, the thioester group in

               inactive C3 is hidden within the folded molecule like a pocket knife.
                  In healthy normal animals, C3 spontaneously breaks down into
               two fragments called C3a and C3b (Fig. 4.3). This breakdown
               exposes the reactive thioester group in C3b. The thioester then
               generates a carbonyl group that covalently binds the C3b to

               carbohydrates and proteins on nearby cell surfaces (Fig. 4.4). The
               breakdown of C3 also exposes binding sites for a protein called
               factor H (FH). When FH binds to these sites, a protease called factor

               I (FI) can then cleave the C3b, preventing further activation and
               generating two fragments, iC3b and C3c. iC3b binds receptors on
               circulating leukocytes (Fig. 4.5). It stimulates these cells to engulf
               pathogens and it activates inflammatory cells. The final breakdown
               product of C3, C3dg, targets pathogens to surface receptors on B

               cells and so promotes antibody production (Chapter 15).























                                                         101
   96   97   98   99   100   101   102   103   104   105   106